rheumon lotio
meda manufacturing gmbh (8036405) - etofenamat - emulsion - etofenamat (12508) 100 milligramm
glasel lotio
meda manufacturing gmbh (8036405) - etofenamat - emulsion - teil 1 - emulsion; etofenamat (12508) 100 milligramm
traumon i.m.
meda manufacturing gmbh (8036405) - etofenamat - injektionslösung - teil 1 - injektionslösung; etofenamat (12508) 1 gramm
rheumon i.m.
viatris healthcare gmbh (8009064) - etofenamat - injektionslösung - etofenamat (12508) 1 gramm
rheumon creme
viatris healthcare gmbh (8009064) - etofenamat - creme - etofenamat (12508) 10 gramm
cartexan 400 mg hartkapseln
laboratory reig jofre sa - chondroitinsulfat-natrium -
demovarin salbe
verfora sa - heparinum natricum - salbe - heparinum natricum 200 u. i., sind, conserv.: propylis parahydroxybenzoas, e 218, excipiens ad-salbe für 1 g. - Épanchements sanguins, neigungen veineuses, varizen - synthetika
cartifit 200 mg/250 mg hartkapseln
laboratorio reig jofre - chondroitinsulfat-natrium; glucosamin hydrochlorid -
bonharen ivn 10 mg/ml injektionslösung für pferde und hunde
contipro a.s. - natriumhyaluronat -
phesgo
roche registration gmbh - pertuzumab, trastuzumab - brustgeschwulste - antineoplastische mittel - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.